Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

NewAmsterdam Pharma Company N.V. (NAMS) vs Zai Lab Limited Unsponsored ADR (ZLAB)

NewAmsterdam Pharma Company N.V. and Zai Lab Limited Unsponsored ADR are both Biotechnology companies. NewAmsterdam Pharma Company N.V. and Zai Lab Limited Unsponsored ADR are of similar size ($2.9B and $2.7B). Zai Lab Limited Unsponsored ADR grew revenue faster over the last twelve months: 5.10% against −88.9%. Zai Lab Limited Unsponsored ADR has the higher net margin (−41.9% vs −3,644.2%) and the lower return on invested capital (−129.3% vs 0.00%). Across the 17 metrics below, Zai Lab Limited Unsponsored ADR leads on 11 and NewAmsterdam Pharma Company N.V. on 6.

Valuation

Metric NAMS ZLAB Biotechnology median
P/E n/m n/m 7.88
P/S 391.19 6.21 11.47
P/B 4.41 4.60 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 301.99 5.14 10.73
Earnings yield (9.57%) (6.85%) (28.84%)
Free cash flow yield (5.16%) (5.82%) (23.03%)

Profitability

Metric NAMS ZLAB Biotechnology median
Gross margin 100.00% 56.47% 65.16%
Operating margin (3,432.20%) (58.74%) 0.00%
Net margin (3,644.21%) (41.86%) 0.00%
Free cash flow margin (2,018.28%) (36.13%) 0.00%
Return on equity (36.81%) (26.91%) (57.72%)
Return on assets (34.16%) (16.81%) (49.22%)
Return on invested capital 0.00% (129.34%) 0.00%

Growth

Metric NAMS ZLAB Biotechnology median
Revenue growth (TTM) (88.87%) 5.10% 5.64%
EPS growth (last fiscal year) 32.81% 38.46% —
Revenue growth, 5-year CAGR — 56.54% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NAMS ZLAB Biotechnology median
Debt to equity 0.00 0.39 0.00
Current ratio 9.03 2.13 4.73
Net debt to EBITDA 2.83 2.66 0.96

Dividend

Metric NAMS ZLAB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric NAMS ZLAB Biotechnology median
Market cap 2.72b 2.85b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack